A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience
Demet ÇekdemirSerkan GüvençFüsun ÖzdemirkıranAli EserTayfur ToptasVildan ÖzkocamazHandan Haydaroğlu ŞahinEsra Ermiş TurakRamazan EsenMelda CömertSevil SadriMuzeyyen Aslaner AkBahar Uncu UluAbdullah KarakuşDerya Selim BaturInci AlacaciogluDemet AydınAtakan TekinalpSinem NamdaroğluFunda CeranPınar TarkunDemet Kiper UnalMustafa ÇetinerMustafa Nuri YenerelAhmet Muzaffer DemirGüven YılmazHatice TerziErden AtillaUmit Yavuz MalkanKadir AcarErman ÖztürkAnil TombakCenk SunuOzan SalimNevin Alayvaz AslanÖzkan SayanÜlkü OzanMesut AyerZafer GökgözNeslihan AndıcEbru KızılkılıçFigen NoyanMehmet ÖzenFunda Pepedil TanrıkuluGüçhan AlanoğluHasan Atilla ÖzkanVahap AslanGuven CetinAlev Akyol ErikçiBurak DeveciFadime Ersoy DursunHasan DermenciPelin AytanMehmet GündüzVolkan KarakusCan ÖzlüSinan DemirciogluOlga Meltem Akay YanarDüzgün ÖzatlıLevent ÜndarEyüp Naci TiftikGülsan Türköz Sucakİbrahim Celallettin HaznedaroğluMuhit ÖzcanMehmet ŞencanMurat TombuloğluGülsüm ÖzetOktay BilgirBurhan TurgutMehmet Ali ÖzcanKadriye Bahriye PayzınMehmet SonmezOrhan AyyıldızMehmet Sinan DalŞehmus ErtopMehmet TurgutTeoman SoysalEmin KayaAli ÜnalMustafa PehlivanIşık AtagündüzTülin Tuğlular FıratlıGuray SaydamReyhan Diz KüçükkayaPublished in: Turkish journal of haematology : official journal of Turkish Society of Haematology (2019)
Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors.